Memory impairment induced by low doses of reserpine in rats: Possible relationship with emotional processing deficits in Parkinson disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1479-1483

  Fernandes, Valéria S ^a   Ribeiro, Alessandra M ^a   Melo, Thieza G ^a   Godinho, Monique ^a   Barbosa, Flavio F ^a   Medeiros, Danielle S ^a   Munguba, Hermany ^a   Silva, Regina H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Animal model; Emotion; Memory; Parkinson disease; Reserpine

Indexed keywords

DRUG VEHICLE; RESERPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVERSION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; EMOTION; EMOTIONAL DISORDER; EMOTIONAL MEMORY; FEAR; FREEZING; LOW DRUG DOSE; MALE; MEMORY DISORDER; MONOAMINE METABOLISM; NONHUMAN; PARKINSON DISEASE; RAT; RECOGNITION; SPATIAL MEMORY; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DATA INTERPRETATION, STATISTICAL; EMOTIONS; FEAR; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; PARKINSON DISEASE; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); RESERPINE; SOCIAL PERCEPTION; SPACE PERCEPTION;

EID: 47749143204     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.05.004     Document Type: Article

References (62)

1. Alves C.S.D., Andreatini R., da Cunha C., Tufik S., and Vital M.A.B.F. Phosphatidylserine reserves reserpine-induced amnesia. Eur J Pharmacol 404 (2000) 161-167
2. Braak H., Braak E., Yilmazer D., de Vos R.A., Jansen E.N., Bohl J., et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol 88 (1994) 493-500
3. Bertrand E., Lechowicz W., Lewandowska E., Szpak G.M., Dymecki J., Kosno-Kruszewska E., et al. Degenerative axonal changes in the hippocampus and amygdala in Parkinson's disease. Folia Neuropathol 41 (2003) 197-207
4. Bowers D., Miller K., Mikos A., Kirsch-Darrow L., Springer U., Fernandez H., et al. Starling facts about emotion in Parkinson's disease: blunted reactivity to aversive stimuli. Brain 129 (2006) 3356-3365
5. Bubser M., and Schmidt W.J. 6-Hydroxydopamine lesion of the rat prefrontal cortex increases locomotor activity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze. Behav Brain Res 37 (1990) 157-168
6. Calzavara M.B., Medrano W.A., Levin R., Kameda S.R., Andersen M.L., Tufik S., et al. Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?. Schizophr Bull 16 (2008) 1-12
7. Carvalho R.C., Patti C.C., Takatsu-Coleman A.L., Kameda S.R., Souza C.F., Garcez-do-Carmo L., et al. Effects of reserpina on the pluz-maze discriminative avoidance task: dissociation between memory and motor impairments. Brain Res 1122 (2006) 176-183
8. Castner J.E., Chenery H.J., Colpland D.A., Coyner T.J., Sinclair F., and Silburn P.A. Semantic and affective priming as a function of stimulation of the subthalamic nucleus in Parkinson's disease. Brain 130 (2007) 1395-1407
9. Colpaert F.C. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26 (1987) 1431-1440
10. Cools R. Dopaminergic modulation of cognitive function-implications for l-Dopa treatment in Parkinson's disease. Neurosci Biobehav Rev 30 (2006) 1-23
11. Cools R., Stefanova E., Barker R.A., Robbins T.W., and Owen A.M. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 125 (2002) 584-594
12. Cools R., Lewis S.J.G., Clark L., Barker R.A., and Robbins T.W. l-Dopa disrupts activity in the Nucleus Accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 32 (2007) 180-189
13. Cooper J., Sagar H.J., Jordan N., Harvey N.S., and Sullivan E.V. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Clin Neuropsychol 14 (1991) 38-55
14. Cox S.M.L., Stefanova E., Johnsrude I.S., Robbins T.W., and Owen A.M. Preference formation and working memory in Parkinson's disease and normal ageing. Neuropsychologia 40 (2002) 317-326
15. Dubois B., Malapani C., Verin M., Rogelet P., Deweer B., and Pillon B. Cognitive function and basal ganglia: the model of Parkinson disease. Rev Neurol 150 (1994) 763-770
16. Fénelon G. Parkinson disease. Medical treatment. Presse Med 26 (1997) 1357-1361
17. Gabrieli J.D.E. Memory systems analyses of mnemonic disorders in aging and age-related diseases. Proc Natl Acad Sci 93 (1996) 13534-13540
18. Gerlach M., and Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103 (1996) 987-1041
19. Giraudo M.D., Gayraud D., and Habib M. Visuoespatial ability of Parkinsonians and elderly adults in location memory tasks. Brain Cogn 34 (1997) 259-273
20. Harding A.J., Stimson E., Henderson J.M., and Halliday G.M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125 (2002) 2431-2445
21. Higginson C.I., King D.S., Levine D., Wheelock V.L., Khamphay N.O., and Sigvardt K.A. The relationship between executive function and verbal memory in Parkinson's disease. Brain Cogn 52 (2003) 343-352
22. Inow T., Li X.B., Abekawa T., Kitaichi Y., Izumi T., Nakagawa S., et al. Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdala. Eur J Pharmacol 497 (2004) 311-316
23. Karel P.M.V.S., Berger H.J.C., Horstink M.W.I.M., Buytenhuijs E.L., and Cools A.R. Executive functions and disease characteristics in Parkinson's disease. Neuropyschologia 34 (1996) 617-626
24. Kliegel M., Phillips L.H., Lemke U., and Kopp U.A. Planning and realisation of complex intentions in patients with Parkinson1s disease. J Neuro Neurosurg Psychiatry 76 (2005) 1501-1505
25. Kokkinidis L., and Anisman H. Interaction between cholinergic and catecholaminergic agents in a spontaneous alternation task. Psychopharmacology 48 (1976) 261-270
26. LeDoux J.E. Emotion circuits in the brain. Annu Rev Neurosci 23 (2000) 155-184
27. Lauterbach E.C. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am 27 (2004) 801-825
28. Lewis S., Dove A., Robbins T.W., Barker R.A., and Owen A.M. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 23 (2003) 6351-6356
29. Lewis S.J.G., Slabosz A., Robbins T.W., Barker R.A., and Owen A.M. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 43 (2005) 823-832
30. Marowsky A., Yanagawa Y., Obata K., and Vogt K.E. A specialized subclass of interneurons mediates dopaminergic facilitation of amygdala function. Neuron 48 (2005) 877-879
31. Marras C., Rochon P., and Lang A.E. Predicting motor decline and disability in Parkinson Disease. Arch Neurol 59 (2002) 1724-1728
32. Matsui H., Udaka F., Mivoshi T., Hara N., Tamura A., Oda M., et al. Frontal assessment battery and brain perfusion image in Parkinson's Disease. J Geriatr Psychiatry Neurol 19 (2006) 41-46
33. Milton A.L., Marshall J.W.B., Cummings R.M., Baker H.F., and Ridley R.M. Dissociation of hemi-spatial and hemi-motor impairments in a unilateral primate model of Parkinson's disease. Behavioral Brain Research 150 (2004) 55-63
34. Monchi O., Petrides M., Mejia-Constain B., and Strafella A.P. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 130 (2007) 233-244
35. Nader K., and LeDoux J. Inhibition of the mesoamygdala dopaminergic pathway impairs the retrieval of conditioned fear associations. Behav Neurosci 133 (1999) 891-901
36. Nagy H., Kéri S., Myers C.E., Benedek G., Shohamy D., and Gluck M.A. Cognitive sequence learning in Parkinson's disease and amnestic mild cognitive impairment: dissociation between sequential and non-sequential learning of associations. Neuropsychologia 45 (2007) 1386-1392
37. Naidu P.S., Singh A., and Kulkarni S.K. Reversal of reserpine-induce orofacial dyskinesia and cognitive dysfunction by quercetin. Pharmacology 70 (2004) 59-67
38. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 67 (2002) 53-83
39. Owen A.M. Cognitive dysfunction in Parkison's Disease: the role of Frontostriatal Circuitry. Neuroscientist 10 (2004) 525-537
40. Owen A.M., James M., Leigh P.N., Summers B.A., Marsden C.D., Quinn N.P., et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 6 (1992) 1727-1751
41. Owen A.M., Doyon J., Dagher A., Sadikot A., and Evans A.C. Abnormal basal ganglia outflow in Parkinson's disease identified with PET: implications for higher cortical functions. Brain 121 (1998) 949-965
42. Penev P.D., Zee P.C., and Turek F.W. Monoamine depletion blocks triazolam-induced phase advances of the circadian clock in hamsters. Brain Res 637 (1994) 255-261
43. Perry J.C., Da Cunha C., Anselmo-Franci J., Andreatini R., Miyoshi E., Tufik S., et al. Behavioural and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats. Eur J Pharmacol 484 (2004) 225-233
44. Phelps E.A. Emotion and cognition: insights from studies of the human amygdale. Annu Rev Psychol 57 (2006) 27-53
45. Pillon B., Deweer B., Vidailhet M., Bonnet A.M., Hahn-Barma V., and Dobois B. Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on 'strategic' processes?. Neuropsychologia 36 (1997) 1-9
46. Pillon B., Ertle S., Deweer B., Sarazin M., Agid Y., and Doubois B. Memory for spatial location is affected in Parkinson's disease. Neuropsychologia 34 (1996) 77-85
47. Pillon B., Ertle S., Deweer B., Bonnet A.M., Vidailhet M., and Dubois B. Memory for spatial location in "de novo" parkinsonian patients. Neurochologia 35 (1997) 221-228
48. Postle B.R., Locascio J.J., Corkin S., and Growdon J.H. The time course of spatial and object learning in Parkinson's disease. Neuropsychologia 35 (1997) 1413-1422
49. Roozendaal B., Okuda S., de Quervain D.J., and McGaugh J.L. Glucocorticoids interact with emotion-induced noradrenergic activation in influencing different memory functions. Neuroscience 138 (2006) 901-910
50. Royer S., Martina M., and Pare D. An inhibitory interface gates impulse traffic between the input and output stations of the amygdala. J Neurosci 19 (1999) 10575-10583
51. Salgado-Pineda P., Delaveau P., Blin O., and Nieoullon A. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol 28 (2005) 228-237
52. Shirahata T., Tsunoda M., Santa T., Kirino Y., and Watanabe S. Depletion of serotonin selectively impairs short-term memory without affecting long-term memory in odor learning in the terrestrial slug Limax valentianus. Learn Mem 13 (2006) 267-270
53. Schneider J.S., and Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 4 (1995) 245-255
54. Schneider K., Habel U., Volkmann J., Regel S., Kornischka J., Sturm V., et al. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry 60 (2003) 296-302
55. Schimitt-Eliassen J., Ferstl R., Wiesner C., Deuschl G., and Witt K. Feedback-based versus observational classification learning in healthy aging and Parkinson's disease. Brain Res 1142 (2007) 178-188
56. Shohamy D., Myers C.E., Grossman S., Sage J., and Gluck M.A. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease. Behav Brain Res 159 (2005) 191-199
57. Shults C.W. Treatments of Parkinson disease. Arch Neurol 60 (2003) 1680-1684
58. Silva R.H., Abílio V.C., Torres-Leite D., Bergamo M., Chinen C.C., Claro F.T., et al. Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice. Behav Brain Res 132 (2002) 171-177
59. Skalisy L.L., Beijamini V., Joca S.L., Vital M.A.B.F., da Cunha C., and Andreatini R. Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson's disease association. Prog Neuro-Psychopharmacol Biol Psychiatry 26 (2002) 879-883
60. Vera-Cuesta H., Vera-Acosta H., Alvarez-González L., Fernández-Maderos I., and Casabona-Fernández E. Frontal dysfunction in idiopathic Parkinson's disease. Ver Neurol 42 (2006) 76-84
61. Yoshitake T., Yoshitake S., Fujino K., Nohta H., Yamaguchi M., and Kehr J. High-sensitive liquid chromatographic method for determination of neuronal release of serotonin, noradrenaline and dopamine monitored by microdialysis in the rat prefrontal cortex. J Neurosci Methods 140 (2004) 163-168
62. Zgaljardic D.J., Foldi N.S., and Borod J.C. Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathogical contributions. J. Neural Transm 111 (2004) 1287-1301